home / stock / bctxf / bctxf news

BCTXF News and Press, BriaCell Therapeutics From 09/20/19

Stock Information
Company Name: BriaCell Therapeutics
Stock Symbol: BCTXF
Market: OTC
Website: briacell.com
Menu
BCTXF BCTXF Quote BCTXF Short BCTXF News BCTXF Articles BCTXF Message Board
Get BCTXF Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTXF - BriaCell announces private placement of up to $0.6M

BriaCell Therapeutics ( OTCQB:BCTXF -19.9% ) announce a non-brokered private placement of up to ~8.57M common shares for gross proceeds of up to ~ C$0.6M at a price of C$0.07/share. More news on: BriaCell Therapeutics Corp., Read more ...

BCTXF - BriaCell Announces Private Placement of up to $600,000

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for adva...

BCTXF - BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) will remain halted for the duration of CEO Dr. Williams ...

BCTXF - BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company will be pres...
BCTXF - BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces tha...

BCTXF - BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...

BCTXF - BriaCell Announces $350,000 Equity Investment by Board of Directors

BERKELEY, Calif. and VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to ...
BCTXF - BriaCell's Novel Technology and Clinical Data Published at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

BERKELEY, Calif. and VANCOUVER, British Columbia, May 28, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced...

BCTXF - BriaCell Approves New Board of Directors and Chairman at Annual and Special Meeting of Shareholders

BERKELEY, Calif., and VANCOUVER, British Columbia, May 13, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announce...

BCTXF - BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

BERKELEY, Calif. and VANCOUVER, British Columbia, April 23, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF) , a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announc...
Previous 10 Next 10